COVID-19 and emerging viral infections: The case for interferon lambda

With the first reports on coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the scientific community working in the field of type III IFNs (IFN-λ) realized that this class of IFNs could play an important role in this and o...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of experimental medicine Vol. 217; no. 5
Main Authors Prokunina-Olsson, Ludmila, Alphonse, Noémie, Dickenson, Ruth E., Durbin, Joan E., Glenn, Jeffrey S., Hartmann, Rune, Kotenko, Sergei V., Lazear, Helen M., O’Brien, Thomas R., Odendall, Charlotte, Onabajo, Olusegun O., Piontkivska, Helen, Santer, Deanna M., Reich, Nancy C., Wack, Andreas, Zanoni, Ivan
Format Journal Article
LanguageEnglish
Published United States Rockefeller University Press 04.05.2020
Subjects
Betacoronavirus - physiology
Coronavirus Infections - metabolism
COVID-19
Humans
Infectious Disease and Host Defense
Interferons - metabolism
Pandemics
Pneumonia, Viral - metabolism
SARS-CoV-2
Viewpoint
Virus Internalization
Online AccessGet full text

Cover

More Information
Summary:With the first reports on coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the scientific community working in the field of type III IFNs (IFN-λ) realized that this class of IFNs could play an important role in this and other emerging viral infections. In this Viewpoint, we present our opinion on the benefits and potential limitations of using IFN-λ to prevent, limit, and treat these dangerous viral infections.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
All authors contributed equally to this paper.
ISSN:0022-1007
1540-9538
1540-9538
DOI:10.1084/jem.20200653